- Home
- ETON vs SPOK Comparison
ETON vs SPOK Comparison
Compare ETON & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- SPOK
- Stock Information
- Founded
- ETON 2017
- SPOK 2004
- Country
- ETON United States
- SPOK United States
- Employees
- ETON N/A
- SPOK N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- SPOK Telecommunications Equipment
- Sector
- ETON Health Care
- SPOK Telecommunications
- Exchange
- ETON Nasdaq
- SPOK Nasdaq
- Market Cap
- ETON 329.8M
- SPOK N/A
- IPO Year
- ETON 2018
- SPOK 1992
- Fundamental
- Price
- ETON $13.93
- SPOK $15.96
- Analyst Decision
- ETON Strong Buy
- SPOK Hold
- Analyst Count
- ETON 3
- SPOK 1
- Target Price
- ETON $27.67
- SPOK $15.00
- AVG Volume (30 Days)
- ETON 243.5K
- SPOK 155.7K
- Earning Date
- ETON 03-18-2025
- SPOK 04-30-2025
- Dividend Yield
- ETON N/A
- SPOK 7.85%
- EPS Growth
- ETON N/A
- SPOK N/A
- EPS
- ETON N/A
- SPOK 0.73
- Revenue
- ETON $39,011,000.00
- SPOK $137,653,000.00
- Revenue This Year
- ETON $107.69
- SPOK $3.51
- Revenue Next Year
- ETON $65.50
- SPOK N/A
- P/E Ratio
- ETON N/A
- SPOK $21.82
- Revenue Growth
- ETON 23.29
- SPOK N/A
- 52 Week Low
- ETON $3.03
- SPOK $13.24
- 52 Week High
- ETON $18.41
- SPOK $17.96
- Technical
- Relative Strength Index (RSI)
- ETON 48.53
- SPOK 42.74
- Support Level
- ETON $12.73
- SPOK $15.68
- Resistance Level
- ETON $15.73
- SPOK $16.13
- Average True Range (ATR)
- ETON 0.94
- SPOK 0.35
- MACD
- ETON 0.01
- SPOK -0.04
- Stochastic Oscillator
- ETON 68.67
- SPOK 32.84
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.